Aluminum hydroxide + Magnesium hydroxide
This medicine should always be used exactly as described in the package leaflet for the patient or as directed by a doctor or pharmacist.
Maalox is a combination medicine with a local anti-acid effect, neutralizing excess hydrochloric acid in gastric juice, and protecting the gastric and duodenal mucosa. It does not cause excessive neutralization of gastric contents and secondary stimulation of acid secretion. Maalox is indicated for the symptomatic treatment of upper gastrointestinal disorders associated with hyperacidity:
Before taking Maalox, the patient should discuss it with a doctor or pharmacist. Particular caution should be exercised when using Maalox:
Children
Using magnesium hydroxide in young children may lead to hypermagnesemia, especially if they have renal impairment or dehydration.
The patient should inform the doctor or pharmacist about all medicines being taken or planned to be taken, as Maalox may affect the action of some medicines or some medicines may affect the action of Maalox. In particular:
As a precaution, the patient should plan to take any oral medicine and antacid at an interval of at least 2 hours (for fluoroquinolones, more than 4 hours).
Concomitant use of Maalox with:
Magnesium hydroxide and other medicines
Magnesium hydroxide may affect the action of some medicines or some medicines may affect the effectiveness of magnesium hydroxide. The patient should inform the doctor or pharmacist if they are taking:
Aluminum hydroxide and citrates may increase aluminum levels in the blood, especially in patients with renal impairment.
The medicine should be taken after a meal.
This medicine may be used during pregnancy only on the advice of a doctor. The patient can continue to take Maalox while breastfeeding.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult a doctor before using this medicine.
No negative effect of Maalox on the ability to drive and use machines has been observed.
If the patient has previously been diagnosed with intolerance to some sugars, they should consult a doctor before taking the medicine.
The medicine contains 140 mg of sorbitol in each sachet.
Sorbitol is a source of fructose. If the patient (or their child) has previously been diagnosed with intolerance to some sugars or has hereditary fructose intolerance, a rare genetic disorder in which the patient's body does not break down fructose, they should consult a doctor before taking the medicine or giving it to their child.
The usual dose is 1-2 sachets when pain occurs, not exceeding 6 doses (12 sachets) per day.
Shake before use.
Before using Maalox in children under 6 years of age, a doctor should be consulted.
In case of suspected overdose, the patient should consult a doctor.
A double dose should not be taken to make up for a missed dose.
If the patient has any further doubts about using this medicine, they should consult a doctor.
Like all medicines, Maalox can cause side effects, although not everybody gets them.
Uncommon (less than 1 in 100 people): diarrhea or constipation.
Very rare (less than 1 in 10,000 people): nausea, vomiting, pale stools.
Frequency not known (frequency cannot be estimated from the available data):
If the patient experiences any side effects, including any possible side effects not listed in the package leaflet, they should inform their doctor or pharmacist. Side effects can be reported directly to the Department of Pharmacovigilance of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181C
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help to gather more information on the safety of this medicine.
There are no special precautions for storage.
The medicine should be kept out of sight and reach of children.
The medicine should not be used after the expiration date stated on the packaging.
The medicine should not be used if visible signs of deterioration are observed.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
Sachets containing 4.3 ml of suspension, packaged in 20 sachets per box.
Marketing authorization holder
Opella Healthcare Poland Sp. z o.o.
ul. Bonifraterska 17
00-203 Warsaw
Manufacturer
Opella Healthcare Italy S.r.l.
Viale Europa 11
21 040 Origgio (VA)
Italy
A.Nattermann &Cie.GmbH
Nattermannallee 1
For more detailed information, please contact:
Opella Healthcare Poland Sp. z o.o.
ul. Bonifraterska 17
00-203 Warsaw
phone: +48 22 280 00 00
Date of last revision of the package leaflet:August 2022
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.